These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19240097)

  • 21. Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions.
    Fugh-Berman A; Brown SR; Trippett R; Bell AM; Clark P; Fleg A; Siwek J
    Acad Med; 2011 May; 86(5):649-54. PubMed ID: 21436662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges at the pharmaceutical-physician boundary.
    Rae-Grant Q
    Can J Psychiatry; 2003 Jun; 48(5):287-8. PubMed ID: 12866332
    [No Abstract]   [Full Text] [Related]  

  • 23. Postscript: follow-up after manuscript submission.
    Valente SM
    Nurse Author Ed; 2002; 12(4):1-3. PubMed ID: 12374000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Publish, perish or prosper?
    Samaranayake L
    J Investig Clin Dent; 2011 Nov; 2(4):221-2. PubMed ID: 25426891
    [No Abstract]   [Full Text] [Related]  

  • 25. How a marriage with big pharma ended in divorce.
    Arie S
    BMJ; 2013 Oct; 347():f6062. PubMed ID: 24103763
    [No Abstract]   [Full Text] [Related]  

  • 26. Conflict of interest or productive collaboration? The pharma: academic relationship and its implications for headache medicine.
    Finkel AG
    Headache; 2006; 46(7):1181-5. PubMed ID: 16866722
    [No Abstract]   [Full Text] [Related]  

  • 27. Interactions between pharmaceutical industry and academia revisited: the University of California at Los Angeles case.
    Kupiec-Weglinski JW
    Transplant Proc; 2003 May; 35(3):1238-9. PubMed ID: 12947916
    [No Abstract]   [Full Text] [Related]  

  • 28. Medical student exposure to and attitudes about pharmaceutical companies.
    Soyk C; Pfefferkorn B; McBride P; Rieselbach R
    WMJ; 2010 Jun; 109(3):142-8. PubMed ID: 20672554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nurses, medical writers, editors can work together ethically.
    Woolley K
    Clin J Oncol Nurs; 2009 Jun; 13(3):261-2. PubMed ID: 19514137
    [No Abstract]   [Full Text] [Related]  

  • 30. Co-authorship--a means to an end.
    Bland M; Batten L
    Nurs Prax N Z; 1998 Jul; 13(2):44-8. PubMed ID: 10481650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A physician peer support writing group.
    Grzybowski SC; Bates J; Calam B; Alred J; Martin RE; Andrew R; Rieb L; Harris S; Wiebe C; Knell E; Berger S
    Fam Med; 2003 Mar; 35(3):195-201. PubMed ID: 12670113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commentary: What's wrong with ghostwriting?
    Elliott C; Landa AS
    Bioethics; 2010 Jul; 24(6):284-6. PubMed ID: 20497172
    [No Abstract]   [Full Text] [Related]  

  • 33. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf.
    Nesi T
    US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444
    [No Abstract]   [Full Text] [Related]  

  • 34. Relations with the pharmaceutical industry.
    Sterns EE
    CMAJ; 1994 Aug; 151(4):414-5. PubMed ID: 8055398
    [No Abstract]   [Full Text] [Related]  

  • 35. Relations with the pharmaceutical industry.
    Lexchin J
    CMAJ; 1994 Aug; 151(4):413-4; author reply 415. PubMed ID: 8055397
    [No Abstract]   [Full Text] [Related]  

  • 36. Look, no strings: publishing industry-funded research.
    CMAJ; 2001 Sep; 165(6):733, 735. PubMed ID: 11584556
    [No Abstract]   [Full Text] [Related]  

  • 37. [Relations between physicians and the pharmaceutical industry].
    Ruiz-Argüelles GJ
    Rev Invest Clin; 1997; 49(1):79-80. PubMed ID: 9229760
    [No Abstract]   [Full Text] [Related]  

  • 38. [Medical publications: real or false authors?].
    Sculier JP
    Rev Med Brux; 2009; 30(2):115-7. PubMed ID: 19517909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ghost marketing: pharmaceutical companies and ghostwritten journal articles.
    Moffatt B; Elliott C
    Perspect Biol Med; 2007; 50(1):18-31. PubMed ID: 17259673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA-industry relations: progress from confrontation to communication.
    Robinson JR
    J Parenter Sci Technol; 1983; 37(4):111-2. PubMed ID: 6620041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.